The Guam Attorney General’s Office is actively engaged in discussion with Purdue Pharma, the giant billion-dollar opioid maker sued by AG Leevin Camacho and many other attorneys general nationwide, which is now settling the many lawsuits it faces.
According to AG Leevin Taitano, any funds that it recovers will be used locally for treatment and rehabilitation, education, monitoring, and enforcement.
“We will continue to investigate and pursue other types of claims impacting Guam’s consumers,” Camacho said.
According to the Associated Press, many state attorneys general and lawyers representing local governments are now in active settlement talks with Purdue Pharma, the maker of the prescription painkiller OxyContin that is facing billions of dollars in potential liability for its role in the nation’s opioid crisis.
A report by NBC News said the privately held company has offered to settle for $10 billion to $12 billion.
Last month, Attorney General Leevin Camacho sued Purdue Pharma L.P. and related companies in local court for violating Guam’s Deceptive Trade Practices Act.
The complaint alleges that Purdue “misled” prescribers and patients about the safety and efficacy of its opioids to increase the company’s profits.
There are similarities in the Guam AG’s lawsuit and the national lawsuits against Purdue Pharma.
For one, the lawsuits in the states assert that the company had an aggressive marketing campaign that sold OxyContin as a drug with a low chance of triggering addictions despite knowing that wasn’t true.
The Guam AG’s complaint alleges that Purdue’s marketing campaign was “deceptive” and that it “downplayed” the dangers of addiction with long-term use.